TMDX Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of 12.65%. TransMedics Group, Inc.'s return on equity of 33.29% beat Electromed, Inc.'s return on equity of 18.89%.

TransMedics Group, Inc. has a consensus price target of $143.00, signalling upside risk potential of 2.07%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.5%. Given that Electromed, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Electromed, Inc. is more attractive than TransMedics Group, Inc..

TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. TransMedics Group, Inc.'s net income of $24.3M is higher than Electromed, Inc.'s net income of $2.1M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 56.59x while Electromed, Inc.'s PE ratio is 29.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 9.67x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of -36.3%. TransMedics Group, Inc.'s return on equity of 33.29% beat Myomo, Inc.'s return on equity of -68.35%.

TransMedics Group, Inc. has a consensus price target of $143.00, signalling upside risk potential of 2.07%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Myomo, Inc. is more attractive than TransMedics Group, Inc..

TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. TransMedics Group, Inc.'s net income of $24.3M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 56.59x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 9.67x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of 7.29%. TransMedics Group, Inc.'s return on equity of 33.29% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

TransMedics Group, Inc. has a consensus price target of $143.00, signalling upside risk potential of 2.07%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Phibro Animal Health Corp. has higher upside potential than TransMedics Group, Inc., analysts believe Phibro Animal Health Corp. is more attractive than TransMedics Group, Inc..

TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

TransMedics Group, Inc. quarterly revenues are $143.8M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. TransMedics Group, Inc.'s net income of $24.3M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 56.59x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 9.67x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of -86.59%. TransMedics Group, Inc.'s return on equity of 33.29% beat Stereotaxis, Inc.'s return on equity of -218.3%.

TransMedics Group, Inc. has a consensus price target of $143.00, signalling upside risk potential of 2.07%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 82.4%. Given that Stereotaxis, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Stereotaxis, Inc. is more attractive than TransMedics Group, Inc..

TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. TransMedics Group, Inc.'s net income of $24.3M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 56.59x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 9.67x versus 6.87x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.